Ricardo Rojo

2.4k total citations · 4 hit papers
37 papers, 1.6k citations indexed

About

Ricardo Rojo is a scholar working on Dermatology, Rheumatology and Immunology and Allergy. According to data from OpenAlex, Ricardo Rojo has authored 37 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Dermatology, 16 papers in Rheumatology and 12 papers in Immunology and Allergy. Recurrent topics in Ricardo Rojo's work include Dermatology and Skin Diseases (18 papers), Rheumatoid Arthritis Research and Therapies (15 papers) and Allergic Rhinitis and Sensitization (12 papers). Ricardo Rojo is often cited by papers focused on Dermatology and Skin Diseases (18 papers), Rheumatoid Arthritis Research and Therapies (15 papers) and Allergic Rhinitis and Sensitization (12 papers). Ricardo Rojo collaborates with scholars based in United States, United Kingdom and Germany. Ricardo Rojo's co-authors include Hernán Valdez, Eric L. Simpson, Marco DiBonaventura, Pinaki Biswas, Claire Feeney, Jacob P. Thyssen, Jonathan I. Silverberg, Thomas Bieber, Gary Chan and Seth Forman and has published in prestigious journals such as New England Journal of Medicine, The Lancet and PLoS ONE.

In The Last Decade

Ricardo Rojo

35 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

2020 313 citations Eric L. Simpson, Rodney Sinclair et al. The Lancet profile →
Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis

2020 289 citations Jonathan I. Silverberg, Eric L. Simpson et al. profile →
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis

2021 287 citations Thomas Bieber, Eric L. Simpson et al. profile →
Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial

2022 134 citations Kristian Reich, Jacob P. Thyssen et al. The Lancet profile →

Peers

Countries citing papers authored by Ricardo Rojo

Since Specialization

Citations

This map shows the geographic impact of Ricardo Rojo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ricardo Rojo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ricardo Rojo more than expected).

Fields of papers citing papers by Ricardo Rojo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ricardo Rojo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ricardo Rojo. The network helps show where Ricardo Rojo may publish in the future.

Co-authorship network of co-authors of Ricardo Rojo

This figure shows the co-authorship network connecting the top 25 collaborators of Ricardo Rojo. A scholar is included among the top collaborators of Ricardo Rojo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ricardo Rojo. Ricardo Rojo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-2 2023 ·American Journal of Clinical Dermatology ·Gil Yosipovitch, Melinda Gooderham, Sonja Ständer, Luz Fonacier, Jacek C. Szepietowski, Mette Deleuran, Giampiero Girolomoni, John Su, Andrew G. Bushmakin, Joseph C. Cappelleri, Claire Feeney, Gary Chan, Andrew Thorpe, Hernán Valdez, Pinaki Biswas, Ricardo Rojo, Marco DiBonaventura, Daniela E. Myers	7
2	Efficacy and safety of abrocitinib monotherapy in adolescents and adults: a post hoc analysis of the phase 3 JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN clinical trial 2023 ·Journal of Dermatological Treatment ·Carsten Flohr, Michael J. Cork, Michael R. Ardern‐Jones, Lawrence F. Eichenfield, S. Barbarot, Claire Feeney, Ricardo Rojo, Irina Lazariciu, (unknown)	10
3	Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial breakdown → 2022 ·The Lancet ·Kristian Reich, Jacob P. Thyssen, Andrew Blauvelt, Kilian Eyerich, Weily Soong, Zakiya P. Rice, Hwanhee Hong, Norito Katoh, Fernando Valenzuela, Marco DiBonaventura, (unknown), Fan Zhang, Claire Clibborn, Ricardo Rojo, Hernán Valdez, Urs Kerkmann	134
4	Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes 2021 ·American Journal of Clinical Dermatology ·Jonathan I. Silverberg, Jacob P. Thyssen, Eric L. Simpson, Gil Yosipovitch, Sonja Ständer, Hernán Valdez, Ricardo Rojo, Pinaki Biswas, Daniela E. Myers, Claire Feeney, Marco DiBonaventura	32
5	Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program 2021 ·American Journal of Clinical Dermatology ·Eric L. Simpson, Jonathan I. Silverberg, Audrey Nosbaum, Kevin Winthrop, Emma Guttman‐Yassky, Karin M. Hoffmeister, Alexander Egeberg, Hernán Valdez, Min Zhang, (unknown), William Romero, Andrew Thorpe, Ricardo Rojo, Susan Johnson	94
6	Economic impact of abrocitinib monotherapy and combination therapy in patients with moderate-to-severe atopic dermatitis: Results from JADE MONO-2 and JADE COMPARE 2021 ·JAAD International ·Melinda Gooderham, Chia‐Yu Chu, Ricardo Rojo, Hernán Valdez, Pinaki Biswas, Michael C. Cameron, Claire Feeney, (unknown), (unknown), Joseph C. Cappelleri, Daniela E. Myers, Marco DiBonaventura	9
7	Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate‐to‐severe atopic dermatitis: an analysis of patient‐reported outcomes 2021 ·Journal of the European Academy of Dermatology and Venereology ·Michael J. Cork, Amy McMichael, Joyce Teng, Hernán Valdez, Ricardo Rojo, Gary Chan, (unknown), Daniela E. Myers, Marco DiBonaventura	24
8	Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial 2021 ·Journal of the American Academy of Dermatology ·Andrew Blauvelt, Jonathan I. Silverberg, Charles Lynde, Thomas Bieber, Samantha Eisman, Jacek Zdybski, (unknown), Eric L. Simpson, Fernando Valenzuela, Paulo Ricardo Criado, Mark Lebwohl, Claire Feeney, Tahira Khan, Pinaki Biswas, Marco DiBonaventura, Hernán Valdez, Michael C. Cameron, Ricardo Rojo	89
9	An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data 2020 ·Drug Safety ·Gerd R Burmester, Jeffrey R. Curtis, Huifeng Yun, Oliver FitzGerald, Kevin Winthrop, Valderílio Feijó Azevedo, William F. C. Rigby, Keith S. Kanik, Cunshan Wang, Pinaki Biswas, Thomas V. Jones, (unknown), Thijs Hendrikx, Sujatha Menon, Ricardo Rojo	34
10	Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial breakdown → 2020 ·The Lancet ·Eric L. Simpson, Rodney Sinclair, Seth Forman, Andreas Wollenberg, Roland Aschoff, Michael J. Cork, Thomas Bieber, Jacob P. Thyssen, Gil Yosipovitch, Carsten Flohr, Nina Magnolo, Catherine Maari, Claire Feeney, Pinaki Biswas, Svitlana Tatulych, Hernán Valdez, Ricardo Rojo	313
11	Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study 2019 ·RMD Open ·Frank Buttgereit, Vibeke Strand, Eun Bong Lee, Jesus Abraham Simón Campos, Dorothy McCabe, (unknown), (unknown), Ricardo Rojo, Judith Hey‐Hadavi	32
12	Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis 2018 ·Medicine ·(unknown), S. Radominski, (unknown), Claiton Viegas Brenol, Cristiano A. F. Zerbini, (unknown), Ermeg L. Akylbekova, Ricardo Rojo, Darío Ponce de León	7
13	Safety of Tofacitinib in the Treatment of Rheumatoid Arthritis in Latin America Compared With the Rest of the World Population 2017 ·JCR Journal of Clinical Rheumatology ·(unknown), (unknown), (unknown), Gustavo Citera, Eduardo Mysler, Oscar Rillo, S. Radominski, Mario H. Cardiel, Juan José Jaller, Carlos Álvarez, Darío Ponce de León, (unknown), (unknown), Kenneth Kwok, Ricardo Rojo	13
14	Tofacitinib, an oral Janus kinase inhibitor, in patients from Mexico with rheumatoid arthritis: Pooled efficacy and safety analyses from Phase 3 and LTE studies 2017 ·Reumatología Clínica ·Rubén Burgos‐Vargas, Mario H. Cardiel, (unknown), César Pacheco‐Tena, Virginia Pascual‐Ramos, Carlos Abud‐Mendoza, Ehab Mahgoub, Mahboob U. Rahman, Haiyun Fan, Ricardo Rojo, (unknown), (unknown)	2
15	Efficacy and Safety of Tofacitinib Monotherapy Versus Combination Therapy in a Latin American Subpopulation of Patients with Rheumatoid Arthritis: A Pooled Phase 3 Analysis 2016 ·JCR Journal of Clinical Rheumatology ·Cristiano A. F. Zerbini, S. Radominski, Mario H. Cardiel, (unknown), (unknown), Gustavo Citera, (unknown), Darío Ponce de León, Elaine Hoffman, Ricardo Rojo	1
16	Herpes zoster in patients with rheumatoid arthritis: pooled analyses of tofacitinib phase 2, 3 and long-term extension studies in a Latin American subpopulation 2016 ·Universidad de Chile ·Cristiano A. F. Zerbini, (unknown), Mario H. Cardiel, (unknown), Gustavo Citera, (unknown), Darío Ponce de León, Elaine Hoffman, Ricardo Rojo	1
17	Predicting the probability of successful efficacy of a dissociated agonist of the glucocorticoid receptor from dose–response analysis 2016 ·Journal of Pharmacokinetics and Pharmacodynamics ·Daniela J. Conrado, Sriram Krishnaswami, Satoshi Shoji, Sheela Kolluri, Judith Hey‐Hadavi, Dorothy McCabe, Ricardo Rojo, (unknown)	17
18	Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies 2016 ·Reumatología Clínica ·S. Radominski, Mario H. Cardiel, Gustavo Citera, Annelise Goecke, Juan José Jaller, (unknown), Pedro C. Miranda, (unknown), (unknown), Kenneth Kwok, Ricardo Rojo, (unknown)	11
19	Parasitological Clearance Rates and Drug Concentrations of a Fixed Dose Combination of Azithromycin-Chloroquine in Asymptomatic Pregnant Women with Plasmodium Falciparum Parasitemia: An Open-Label, Non-Comparative Study in Sub-Saharan Africa 2016 ·PLoS ONE ·Kamija S. Phiri, Joshua Kimani, George Mtove, Qinying Zhao, Ricardo Rojo, Jeffery Robbins, Stephan Duparc, Ayman Ayoub, (unknown)	12
20	SAT0221 Efficacy and Safety of PF-04171327, a Novel Dissociated Agonist of the Glucocorticoid Receptor (DAGR): Results of a Phase 2, Randomized, Double-Blind Study 2015 ·Annals of the Rheumatic Diseases ·Frank Buttgereit, Vibeke Strand, (unknown), Dorothy McCabe, Sheela Kolluri, (unknown), Ricardo Rojo, J. Hey‐Hadavi	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact